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Research
Randomized controlled trial of standard versus double dose
cotrimoxazole for childhood pneumonia in Pakistan
Zeba A. Rasmussen,1 Abdul Bari,2 Shamim Qazi,3 Gul Rehman,3 Iqbal Azam,1 SherBaz Khan,4 Farida Aziz,5
Sadia Rafi,6 Mehr Taj Roghani,7 Imran Iqbal,8 Abdul Ghaffar Nagi,9 Waqar Hussain,10 Nahida Bano,1 late
J.C. van Latum,4 & Mushtaq Khan3 for the Pakistan COMET (Cotrimoxazole Multicentre Efﬁcacy Trial) Study Group

Objective Increasing concern over bacterial resistance to cotrimoxazole, which is recommended by WHO as a ﬁrst-line drug for
treating non-severe pneumonia, led to the suggestion that this might not be optimal therapy. However, changing to alternative
antimicrobial agents, such as amoxicillin, is costly. We compared the clinical efﬁcacy of twice-daily cotrimoxazole in standard versus
double dosage for treating non-severe pneumonia in children.
Methods A randomized controlled multicentre trial was implemented in seven hospital outpatient departments and two community
health programmes. A total of 1143 children aged 2–59 months with non-severe pneumonia were randomly allocated to receive
4 mg trimethoprim plus 20 mg sulfamethoxazole/kg of body weight or 8 mg trimethoprim plus 40 mg sulfamethoxazole/kg of body
weight orally twice-daily for 5 days Treatment failure occurred when a child required a change of therapy, died or was lost to follow-up.
Children required a change of therapy if their condition worsened (they developed chest indrawing or danger signs) or if at 48 hours
after enrolment, their clinical condition was the same (deﬁned as having a respiratory rate that was 5 breaths/minute higher or lower
than at the time of enrolment).
Findings The results of 1134 children were analysed: 578 were assigned to the standard dose of cotrimoxazole and 556 to the double
dose. Treatment failed in 112 children (19.4%) in the standard group and 118 (21.2%) in the double-dose group (relative risk 1.10;
95% conﬁdence interval = 0.87–1.37). Using multivariate analysis we found that treatment was more likely to fail in children who
were not given the medicine correctly (P = 0.001), in those younger than 12 months (P = 0.004), those who had used antibiotics
previously (P = 0.002), those whose respiratory rate was  20 breaths/minute above the age-speciﬁc cut-off point (P = 0.006),
and those from urban areas (P = 0.042).
Conclusion Both standard and double strength cotrimoxazole were equally effective in treating non-severe pneumonia. Close followup of patients is essential to prevent worsening of disease. Deﬁnitions of clinical failure need to be more speciﬁc. Surveillance in both
rural and urban areas is essential in the development of treatment policies that are based on clinical outcomes.
Keywords Trimethoprim-sulfamethoxazole combination/administration and dosage/therapeutic use; Pneumonia, Bacterial/drug therapy;
Treatment failure; Child; Randomized controlled trials; Multicenter studies; Pakistan (source: MeSH, NLM).
Mots clés Triméthoprime-sulfaméthoxazole, Association/administration et posologie/usage thérapeutique; Pneumonie bactérienne/
chimiothérapie; Echec thérapeutique; Enfant; Essai clinique randomisé; Etude multicentrique; Pakistan (source: MeSH, INSERM).
Palabras clave Combinación trimetoprim-sulfametoxazol/administración y dosiﬁcación/uso terapéutico; Neumonía bacteriana/
quimioterapia; Insuﬁciencia del tratamiento; Niño; Ensayos controlados aleatorios; Estudios multicéntricos; Pakistán (fuente: DeCS,
BIREME).
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Treatment of childhood pneumonia in Pakistan with cotrimoxazole

Introduction
WHO estimates that 1.9 million deaths occur every year from
lower respiratory infections, primarily pneumonia, mostly in
developing countries (1). Because Streptococcus pneumoniae and
Haemophilus inﬂuenzae are the most common causes of childhood bacterial pneumonia in developing countries, WHO, using
standardized case management guidelines, recommends using
oral cotrimoxazole or amoxicillin to treat non-severe pneumonia at ﬁrst-level health facilities (2, 3).
Pneumonia is a leading cause of death among children in
Pakistan. In 1989, the Government of Pakistan adopted WHO’s
recommendation to use oral cotrimoxazole as ﬁrst-line outpatient treatment for non-severe pneumonia because of its cost,
twice-daily dosage schedule, efﬁcacy and wide availability (4).
While high rates of resistance in nasopharyngeal and blood isolates were documented from 1986 to 1994 (5–8), studies in the
early 1990s showed that cotrimoxazole was effective in treating more than 90% of children who had community-acquired
pneumonia (9, 10). A 1991–92 hospital-based study found no
difference in clinical efﬁcacy between twice-daily cotrimoxazole
and thrice-daily amoxicillin for treating non-severe pneumonia
(failure rates of 13% and 12%, respectively) (11).
Changing from cotrimoxazole to amoxicillin would cost
an estimated US$ 25 million yearly in Pakistan, a signiﬁcant
proportion of the national health budget (12). Due to the faster
elimination of one component of cotrimoxazole (trimethoprim)
in young children, higher doses are needed to achieve plasma
concentrations comparable to those observed in adults, leading
to the suggestion that the daily dose of trimethoprim should
be increased by 100% for younger children (13). We evaluated
the clinical effectiveness of cotrimoxazole in standard versus
double doses to treat children with non-severe pneumonia.

Methods
Patients
We conducted a randomized controlled double-blind multicentre trial in seven urban and two rural sites, one with dispersed health centres (Table 1). Children were seen in hospital
outpatient or community clinics. Free and informed consent
was obtained from children’s parents; procedures followed for
obtaining consent were in accordance with the ethical standards
of the Declaration of Helsinki (14). The National ARI Control
Programme in Pakistan approved the study.
Children aged 2–59 months presenting with cough and
difﬁcult or fast breathing (tachypnoea) were assessed using the
standard WHO acute respiratory infection (ARI) algorithm,
which has been shown to have a sensitivity and speciﬁcity of
80% for the diagnosis of pneumonia (2, 3). Children were
classiﬁed as having non-severe pneumonia if their respiratory
rate was  50 breaths per minute and they were aged 2–11
months and if their respiratory rate was  40 breaths per minute if they were aged 12–59 months. Children were classiﬁed as
having severe pneumonia if they had lower chest wall indrawing
(with or without tachypnoea); they were classiﬁed as having
very severe disease if one or more danger signs were present
(convulsions, drowsiness, inability to drink, stridor in a calm
child, and clinically severe malnutrition).
The respiratory rate used for assessment was the average
of two readings taken for 1 minute each when the child was
quiet, feeding or asleep. Children who were wheezing received
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nebulized or inhaled salbutamol and were reassessed for tachypnoea after 30 minutes. Febrile children received paracetamol.
Children with non-severe pneumonia constituted our
study population. Excluded were children with severe pneumonia, very severe disease, stridor, acute nonpulmonary or underlying chronic illness (including asthma, which was deﬁned as a
history of wheezing  3 times if wheezing was present at the
current evaluation), history of cotrimoxazole allergy, administration of WHO-recommended antimicrobials in appropriate
doses during the previous 48 hours, or if the parents declined
to participate. Children with severe malnutrition were excluded
because WHO recommends they be referred to secondary care
facilities for inpatient therapy (2). To ensure follow-up, at home
if needed, only children living within the municipal limits of
urban sites and walking distance (< 5 km) of the clinic in rural
sites were enrolled.
A senior clinician supervised the study at every site. In
urban sites, study physicians collected data. In rural sites, “lady
health visitors” (a recognized category of paramedical workers in
Pakistan) collected data under the supervision of a study physician. Study personnel were trained in standard ARI case management and study methodology at the coordinating centre, the
Children’s Hospital in Islamabad; at rural sites, study personnel
trained the lady health visitors assigned to peripheral health
centres. The study coordinator visited every site.
A randomization scheme for 200 patients was generated
for each site using a computer program that allocated patients to
uneven blocks of two, four and six patients. To cater for children
of different weights, two bottles of medicine were prepared for
each code. Each site received an equal number of each strength
of cotrimoxazole packaged in identical bottles with the same
appearance and taste: standard strength (200 mg sulfamethoxazole plus 40 mg trimethoprim per 5 ml suspension) and double
strength (400 mg sulfamethoxazole plus 80 mg trimethoprim
per 5 ml suspension). The randomization list with unique identiﬁcation numbers was kept by the company preparing the cotrimoxazole and a health professional who randomly allocated the
drugs but who was not involved in study implementation. Drug
assignment was concealed from parents and study personnel.
The code was broken after primary analysis of the data.
Data were not collected on all children eligible for enrolment, however, efforts were made to recruit as many children as
possible. Children meeting entry criteria were enrolled by study
personnel and randomly allocated, after informed witnessed
verbal consent was obtained, to receive a uniquely coded set of
two bottles containing the same strength of cotrimoxazole to be
given twice daily for ﬁve days: 4 mg trimethoprim plus 20 mg
sulfamethoxazole per kg of body weight (standard dose) or 8 mg
(double dose) trimethoprim plus 40 mg sulfamethoxazole per
kg of body weight.
All mothers received standard ARI home management
instructions (feed the child, increase the intake of ﬂuids, soothe
the throat and relieve cough with safe local remedies, such as
honey water or green tea) that emphasized they should watch for
worsening symptoms (chest indrawing or other danger signs)
and that they should bring the child in at any time if they had
concerns. The proper dose and frequency and duration of administration of the drug were carefully explained. Compliance
was evaluated at each follow-up visit. Children were considered
to have been receiving the correct dose if the mother reported
giving the prescribed dose; bottles were checked to estimate if
80% of the required dose had been given.
11
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Table 1. Characteristics of 1134 children with non-severe pneumonia enrolled in study of standard dose versus double dose
treatment with cotrimoxazole, by treatment group
Characteristics

Treatment group
Standard dose (n = 578)

Double dose (n = 556)

Site of enrolment
Abbottabad
Gilgit (Oshikandass village, rural)
Gilgit (rural, dispersed centres in periphery)
Islamabad
Karachi
Lahore
Multan
Peshawar
Quetta
Urban

16 (2.8)b
76 (13.1)
56 (9.7)
88 (15.2)
74 (12.8)
28 (4.8)
100 (17.3)
99 (17.1)
41 (7.1)
446 (77.2)

13 (2.3)
74 (13.3)
49 (8.8)
84 (15.1)
69 (12.4)
39 (7.0)
99 (17.8)
100 (18.0)
29 (5.2)
433 (77.9)

Agec
2–11 months
12–59 months

11 (5–21)
297 (51.4)
281 (48.6)

11 (5-21)
280 (50.4)
276 (49.6)

Male

369 (63.8)

330 (59.4)

History at baseline
No. of days ill prior to presentationc
Fever
Cough
Difﬁculty breathing
Tight chest binding
Documented antibiotic use in past 7 daysd
Wheezing  3 times at any time in the past
Vomiting
Diarrhoea

3 (2–5)
511 (88.4)
552 (95.5)
313 (54.2)
8 (1.4)
20 (3.5)
23 (4.0)
152 (26.3)
97 (16.8)

3 (2–5)
491 (88.3)
531 (95.5)
319 (57.4)
8 (1.4)
28 (5.0)
22 (4.0)
148 (26.6)
104 (18.7)

Current breastfeedinge
Age 2–11 months
Age 12–23 months

257 (44.5)
105 (18.2)

238 (42.8)
93 (16.7)

a

Examination at baseline
Respiratory ratec
2–11 months
12–59 months
High respiratory ratef
Wheezing
2–11 months
12–59 months
Malnourishedg
Weight-for-age scorec
During the study
Was not given medicine correctly
Wheezing at any time after enrolment
a

b
c
d
e
f

g
h
i

12

58.0 (54.5–62.0)
50.0 (46.0–55.5)
54 (9.3)
149 (25.8)
103 (34.7)
46 (16.4)
88 (15.3) h
-0.82 (-1.64 – -0.11)
33 (5.7)
159 (27.5)

59.0 (55.5–63.0)
50.0 (45.0–54.0)
63 (11.3)
144 (25.9)
79 (28.2)
65 (23.6)
87 (15.7) i
-0.90 (-1.67 – 0.03)
31 (5.6)
157 (28.2)

As deﬁned by the local government urban areas have > 5000 inhabitants, educational and health facilities, infrastructure, a post ofﬁce and are areas where
most of the population works in nonagricultural sectors. Rural areas are those that have  5000 inhabitants and where the majority of the population works in
agriculture.
Values in parentheses are percentages unless otherwise indicated.
Values are medians (interquartile range).
Assessed by either the presence of a prescription, presence of a medicine bottle or parent or caretaker knowing the name of the antibiotic.
18 children  2 years old in the group receiving the standard dose and 20 in the group receiving the double dose were being breastfed.
A high respiratory rate was one in which the child had  20 breaths/minute above the age-adjusted WHO threshold for tachypnoea, that is  70 for children
aged 2–11 months and  60 for those aged 12–59 months.
Weight-for-age scores > 2 standard deviations below normal (15).
n = 575.
n = 553.
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After enrolment (day 0), children were reassessed on day
2 and day 5, and if they had not been receiving the correct dose
or if therapy was changed (see below) they were also seen on day
7; examination was generally done by the same person. Children
not presenting for scheduled follow-up visits were assessed at
home the next day, or if they were unable to be traced they were
considered lost to follow-up. At follow-up visits, clinical assessment was based on the mother’s opinion of the child’s condition
and the health worker’s assessment. Children were considered to
have improved if they had a slower respiratory rate (either within
the normal range for their age, or > 5 breaths/minute lower than
at the time of the previous evaluation); they were considered to
be the same if there was persistent tachypnoea (their respiratory
rate was 5 breaths/minute higher or lower than at the time of
previous evaluation) without chest indrawing or danger signs.
A child’s condition was considered to have worsened if he or she
had developed severe pneumonia or very severe disease. Patients
whose condition worsened were referred for inpatient parenteral
treatment with benzylpenicillin, ampicillin or chloramphenicol.
If parenteral therapy could not be given, oral chloramphenicol
(25 mg/kg every 6 hours) was prescribed.
Children whose condition had improved on day 2 continued cotrimoxazole until day 5, or if they had not been given
the medicine as prescribed they continued until day 7. If a child
had been given the drug correctly and his or her condition
was considered to be the same on day 2 or day 5, therapy was
changed to oral amoxicillin (15 mg/kg every 8 hours). Children
who had not been given their medicine correctly and whose
condition was the same on day 2 continued with cotrimoxazole
for 2 more days and were then reassessed; if their condition remained the same, the drug was changed to amoxicillin. Children
whose treatment was changed to amoxicillin were re-evaluated
every 48–72 hours after changing medication until cured. Children who did not improve after 48 hours on amoxicillin were
referred for parenteral therapy.
Clinical cure was deﬁned as improvement with return of
respiratory rate to the age-speciﬁc normal range. The primary
outcomes were deﬁned as treatment success (resolution on cotrimoxazole) and treatment failure (change of therapy, death or
loss to follow-up).

Statistical analysis
The sample size was calculated to show a 5% difference in
treatment outcomes between children receiving standard dose
and those receiving double dose cotrimoxazole. Our hypothesis
was that the failure rate would be lower with the double dose
of cotrimoxazole (5%) than with the standard dose (10%) (9,
10). With α = 0.05 and a power of 80%, a sample size of 474
children in each group was needed.
Data were recorded on autocopy data forms, one of which
was kept on-site and one of which was sent to the coordinating
centre. Double data entry was performed at two sites (Children’s
Hospital, Islamabad, and Aga Khan Health Service, Gilgit)
and validated using Epi Info software version 6, (Centers for
Disease Control and Prevention, Atlanta, GA, USA). The range
and internal consistency of the data were checked. Analysis was
carried out using Epi Info and the SPSS software package version 10 (SPSS Inc., Chicago, IL, USA).
Baseline characteristics of the two treatment groups were
compared. Outcomes for the groups were compared using an
estimation of relative risk with 95% conﬁdence intervals (CIs).
Data were compared for the treatment success and treatment
Bulletin of the World Health Organization | January 2005, 83 (1)

failure groups. Univariate analysis of categorical variables included estimates of relative risks and 95% CIs and the Student’s
t-test for continuous variables; for the t-test, only P-values are
reported.
Multivariate logistic regression analysis was carried out to
identify the determinants of treatment failure. In all analyses
the treatment group indicator was retained to reﬂect the original design of the study. To ensure our results were relevant to
the management of pneumonia at the programme level, we
categorized some continuous variables, such as age, duration
of illness and respiratory rate, for logistic regression analysis.
Malnutrition was deﬁned as weight-for-age scores that were
>2 standard deviations below normal (15).

Findings
Between October 1995 and July 1996, 1143 children were
enrolled in the study. The analysis of the primary outcome
involved 1134/1143 patients, excluding 8 who were incorrectly
enrolled and 1 who did not received the allocated intervention.
After excluding these 9 cases of protocol violation, 578 children received the standard dose and 556 received the double
dose of cotrimoxazole (Fig. 1). Thus these children received
the intended treatment and their results were analysed for the
primary outcome measure.
The median age of the children was 11 months (interquartile range = 5–21 months); 577 children (50.9%) were younger
than 12 months old. Baseline and intrastudy characteristics are
presented in Table 1. At enrolment, wheeze was more frequent
in children aged < 12 months of age (182/577; 31.5%) than in
older children (111/557; 19.9%) (relative risk (RR) 1.58; 95%
CI = 1.29–1.94).
Treatment failure occurred in 230 children (20.3%)
(Fig. 1). Clinical success was similar in the standard dose and
double dose groups: 466 children in standard dose group
(80.6%) and 438 in the double dose group (78.8%) (RR = 1.10;
95% CI = 0.87–1.37). A total of 32 children (2.8%) were lost to
follow-up. In the standard dose group, drug treatment was withdrawn in 5 children because of rash (0.7%); it was withdrawn
from 1 child (0.2%) in the double dose group. The difference
was not signiﬁcant (RR = 3.85; 95% CI = 0.43–34.32). No
serious side-effects occurred.
Of the 198 children requiring a change of therapy
(Fig. 2), 161 (81.3%) were cured on amoxicillin, 1 (0.5%)
was cured with chloramphenicol, 24 (12.1%) on parenteral
antibiotics, 1 died (3-month-old hospitalized male with very
severe disease), and the ﬁnal outcome of 11 children (5.5%)
was unknown. Of these 11, 7 were referred to hospital; 3 had
had their drug changed to amoxicillin; and 1 had cotrimoxazole stopped due to rash. Three had improved at the time of
their last follow-up.
On day 2, 910/1134 children (80.2%) were classiﬁed as
improved; 133 (11.7%) were the same; and 68 (6.0%) were
worse. Altogether 23 children (2.0%) were not seen (18 lost
to follow-up, 5 cured on cotrimoxazole). There was no signiﬁcant difference between the two treatment groups among the
children at the ﬁrst follow-up visit. Of 68 whose condition
deteriorated, 41 developed severe pneumonia and 27 developed
very severe disease (Fig. 2). Of the 910 children who improved,
33 subsequently required a change of therapy. Of the 133 who
remained the same, the drug treatment was changed according
to protocol in 87 but not changed according to protocol in 46;
35 of these 46 children (76.0%) recovered on cotrimoxazole.
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Fig. 1. Flowchart showing how patients proceeded through the study

1143 children randomizeda

560 allocated
double dose
cotrimoxazole

583 allocated
standard dose
cotrimoxazole

4 excluded
All enrolled incorrectlyc

5 excluded
4 enrolled incorrectlyb
1 received bottle with
two codes and drug strengths

578 analysed

First follow-up
(Day 2)

556 analysed

87 treatment failures
(9 lost to follow-up)

91 treatment failures
(9 lost to follow-up)

487 continued treatment

Second follow-up
(Day 5)

469 continued treatment

29 treatment failures
(7 lost to follow-up)

17 treatment failures
(1 died)
(7 lost to follow-up)

446 clinically cured

24 continued treatment

28 continued treatment

44treatment
treatmentfailures
failures

Third follow-up
(Day 7)

2 treatment failures

20 clinically cured

a

412 clinically cured

26 clinically cured

Clinically cured

466 (80.6%)

438 (78.8%)

Treatment failures

112 (19.4%)

118 (21.2%)

Change in therapyd

96 (16.6%)

102 (18.3%)

Lost to follow-up

16 (2.8%)

16 (2.9%)

Uniform information on all eligible patients is not available.

b

3 children did not have pneumonia and 1 with age unspecified; all cured after 5 days of cotrimoxazole treatment.

c

2 children without pneumonia, 1 with severe pneumonia, 1 with severe malnutrition; first 3 cured after 5 days of cotrimoxazole treatment.

d

Includes 1 death.

Treatment failed for last child who required parenteral therapy for cure.
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First follow-up

Fig. 2. Treatment details for the 198/1134 children treated with single dose or double dose cotrimoxazole who needed a change
in treatment for non-severe pneumonia

Children needing
to change treatment
(n = 198)

Condition worse (n = 68)a
Severe pneumonia (n = 41)
Very severe disease (n = 27)

Medicine continued
(n = 10)b

Medicine changed

Second follow-up

Condition improving (n = 33)
Pneumonia (n = 26)
No pneumonia (n = 7)

Condition the same
(pneumonia)
(n = 97)

Condition worse
(n = 5)f
Severe pneumonia
(n = 2)
Very severe disease
(n = 3)

Medicine
changed

Condition
the same
(pneumonia)
(n = 3)

Medicine changed
(n = 87)c

Condition
improving
(pneumonia)
(n = 2)

Medicine
continued
(n = 1)

Medicine
changed
(n = 1)g

Medicine continued
(n = 28)

Condition worse
(n = 3)
Severe pneumonia
(n = 2)
Very severe disease
(n = 1)

Third follow-up
a

Condition
the same
(pneumonia)
(n = 23)

Condition the same
(pneumonia)
(n = 3)
Medicine changed

Condition
improving
(pneumonia)
(n = 2)

Medicine
continued
(n = 2)

Medicine
changed

Medicine
continued
(n = 3)h

Condition the same
(pneumonia)
Medicine changed

Medicine changed
(n = 4)d
or stoppede (n = 1)

Medicine
changed
(n = 20)

Condition the same
(pneumonia)
(n = 2)
Medicine changed

Includes 1 death.

b

1 not given medicine correctly; protocol for changing medicine not followed in 9 children.

c

Includes 1 child who developed rash.

d

3 children developed rash, 1 still had fast breathing. Drug changed on clinical grounds.

e

Child developed rash.

f

1 child became worse before scheduled second follow-up and medicine was changed.

g

Child still appeared sick and had high respiratory rate.

h

1 not given medicine correctly; protocol for changing medicine not followed in 2 children.

Fifty-seven children whose condition should have been
classiﬁed as being the same at their ﬁrst follow-up visit were
considered to have improved and therapy was not changed;
53 of these children (93.0%) recovered on cotrimoxazole. Of
the 103 children (46 + 57) who should have had their therapy
changed but did not, 85% recovered on cotrimoxazole. Half
of these 103 children had a decrease in their respiratory rate
of 3–5 breaths/minute.
A total of 1070/1134 (94.3%) children received the correct dose of medicine for the correct length of time. There were
2337 follow-up visits, of which 16% were at home; medicine
bottles were checked at 92% of visits.
When the treatment groups were combined, univariate
analysis showed that children were at a greater risk of treatment
Bulletin of the World Health Organization | January 2005, 83 (1)
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failure if at enrolment they were < 12 months of age, had had
a longer duration of illness, had used antibiotics in the previous 7 days, had a high respiratory rate ( 20 breaths/minute
above the age-speciﬁc cut-off point), had a history of tight
chest-binding (the practice of wrapping a child’s chest tightly
with cloth, which in some areas of the country is thought to
be therapeutic), and lived in urban centres (Table 2, available
only on the web version at http://www.who.int/bulletin). Also
at higher risk of treatment failure were children who were not
given the medicine correctly or who had wheezing at any time
after enrolment.
Logistic regression modelling was used to adjust for possible confounding and interaction effects (Table 3). In the best
multivariate model the following variables were signiﬁcantly
15
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Table 3. Multivariate analysis of predictors of therapy failure
among 1134 children treated for non-severe pneumonia
with either standard dose or double dose cotrimoxazole
Variable
Age < 12 months
Antibiotic use in past 7 days
High respiratory rate at baselineb
Living in urban area at baseline
Child not given medicine correctly
Strength of cotrimoxazole
Wheezing any time after
enrollment
a
b

Adjusted
relative riska

P-value

1.42 (1.11–1.79)
1.96 (1.29–2.74)
1.58 (1.14–2.10)
1.39 (1.00–1.87)
2.00 (1.37–2.70)
1.07 (0.84-1.34)
1.24 (0.96-1.58)

0.005
0.003
0.007
0.047
0.001
0.588
0.094

Values in parentheses are 95% conﬁdence intervals.
A high respiratory rate was one in which the child had  20 breaths/
minute above the age-adjusted WHO threshold for tachypnoea, that is  70
for children aged 2–11 months and  60 for those aged 12–59 months.

associated with treatment failure although strength of cotrimoxazole was not: age < 12 months, high respiratory rate at
enrolment, previous antibiotic use, urban status and treatment
not given correctly.
The failure rate was 14.9% (38/255) in the two rural areas
compared with 21.8% (192/879) in the urban areas (RR = 0.68;
95% CI = 0.50–0.94) when both treatment groups were combined. The lowest failure rate (10/105, 9.5%) was in a rural programme that had many dispersed health centres. Children from
urban centres were more likely to be younger and better nourished, present later in the course of their illness, have a history
of antibiotic use as well as have a cough, difﬁculty breathing,
vomiting, and wheeze at any time after enrolment (Table 4,
available only on the web version at http://www.who.int/bulletin).
They were less likely to have a history of asthma and more likely
to have been given their medicine correctly.

Discussion
Clinical efﬁcacy of cotrimoxazole
The results show that there was no signiﬁcant difference between the clinical efﬁcacy of the standard dose of cotrimoxazole
and the double dose when given twice daily to treat children
with non-severe pneumonia. As in two other studies (16, 17),
the clinical failure rate was comparatively high; however, in this
study follow-up was good (and it was also very good in the
other two studies cited), and almost all children with non-severe
pneumonia for whom treatment failed were cured when given
amoxicillin. Few children required parenteral therapy.
The failure rate of cotrimoxazole in this study is higher
than the 9% reported in community-based studies (9, 10) and
the 13% reported in a hospital-based study (11) from the early
1990s, but it is similar to the failure rate from a later study (16).
These differences could be due to temporal changes or to differences in the deﬁnition of failure. It is critical to have a standardized deﬁnition of clinical failure to detect trends over time. If
failure rates are increasing then other antimicrobial regimens for
treating non-severe pneumonia need to be explored. Repeating
this study in other countries that have had similar failure rates
with cotrimoxazole would be useful in conﬁrming the generalizability of our results.
16
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As in previous studies (11, 16, 17), we found that treatment failure was signiﬁcantly associated with younger age, high
initial respiratory rate and not being given the treatment correctly. We identiﬁed new risk factors of previous antibiotic use
and living in an urban area. Children with these risk factors thus
require special attention and counselling.
The high treatment failure rate could have been caused
by: increasing resistance of S. pneumoniae and H. inﬂuenzae to
cotrimoxazole, viral etiology, a high incidence of underlying
hyperactive airway disease, and/or our use of sensitive criteria
to assess therapy failure. We have previously discussed the ﬁrst
three factors (15). In this study, children who had already used
antibiotics were twice as likely to be failed by treatment, suggesting that their infection could be due to resistant bacteria.

Deﬁnition of therapy failure
The deﬁnition of therapy failure was sensitive: children whose
condition was considered to be the same on day 2 had a change
in therapy and were classiﬁed as having had treatment failure.
To be classiﬁed as improved on day 2, children had to have a
decrease in their respiratory rate of > 5 breaths/minute. WHO
guidelines for improvement are “slower breathing, less fever,
eating better” (2, 3); these are nonspeciﬁc and could be clariﬁed further. If we had deﬁned improvement as a decrease in
respiratory rate of > 3 or 4 breaths/minute, it is possible that
the failure rate would be lower. Notably, of the 103 children
who according to the respiratory criteria on day 2 should have
had their drug changed but did not, 85% recovered. They may
have been “slow responders” to therapy or had viral infections
or hyperactive airway disease. If a similar proportion of the 87
children whose condition was classiﬁed as being the same on
day 2 and who had a change in therapy had also recovered without therapy change, then our failure rate would have been only
13.8%. Further work is required to improve the speciﬁcity of
criteria for clinical failure, perhaps by more closely monitoring
children whose condition is the same on day 2 for up to 5–7
days in order to determine indicators of subsequent worsening.
We found WHO ARI case management guidelines useful. Re-evaluation at day 2 was appropriate since 68/76 (89.4%)
of those who became worse were detected on day 2. In total,
80% of children requiring a change of therapy responded well to
oral amoxicillin. Counselling and follow-up after 2 days resulted
in a minimal loss to follow-up.

Urban areas versus rural areas
Living in an urban area was a risk factor for failure. The low
failure rate among rural children, as found in other community
studies (9, 10, 18), emphasizes the need to conduct periodic
surveillance of clinical effectiveness in rural areas especially since
the majority of Pakistan’s population (19), and that in many
other developing countries, lives in rural areas. Most policies
on managing childhood illnesses are based on data from urban
settings often because the inclusion of rural areas is logistically
difﬁcult. If rural areas are consistently found to have lower rates
of failure, a ﬂexible treatment policy that speciﬁes distinct ﬁrstline therapies for rural and urban areas may be necessary.

Limitations and strengths
The study would have been more generalizable if all children
had been treated according to the protocol; however, this did
not materially affect our conclusions. The study design would
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have been improved by including a control group treated with
amoxicillin but for reasons of cost (amoxicillin treatment would
have cost four times more than cotrimoxazole treatment) and
sample size (we would have needed to recruit about 600 more
children), we could not do this. The study would have been
more complicated if amoxicillin was given three times daily,
and adding a third (placebo) dose to the cotrimoxazole group
may have resulted in decreased compliance in the cotrimoxazole
groups. However, in two subsequent studies (16, 17), clinical
response to amoxicillin has been similar to that found with
cotrimoxazole. These studies were done in similar sites in Pakistan at the same time of year with comparable populations. We
would expect the etiological agents for community-acquired
pneumonia (bacterial being primarily S. pneumoniae and H.
inﬂuenzae) to have been the same in all three studies, as has been
determined in other studies in Pakistan (7, 11, 20) and in other
developing countries (3).
Other limitations of our study include the lack of microbiological data, chest radiographs, detailed clinical examination
and a longer follow-up period. Given the high incidence of
pneumonia in the community in low-resource settings, it is
impractical and expensive to obtain chest radiographs and do
pulse oximetry, blood cultures or lung punctures in all children
with suspected pneumonia. Even if, as part of the study, standard
investigations were obtained for all patients, it would not have
been possible to generalize the results to other low-resource settings, where pneumonia is not diagnosed using these methods.
The intention of this study was to use the WHO ARI guidelines,
which do not recommend such investigations for diagnosing
pneumonia in the ﬁeld.
The strengths of our study include the good follow-up
rates, high rates of compliance with treatment, low mortality,
inclusion of paramedical workers and of urban and rural sites
in different geographical areas of the country. Our ﬁnding that
with intermittent supervision paramedical workers in rural areas

could successfully evaluate patients suggests that such workers
can be used to assess the clinical effectiveness of pneumonia
therapy, as has successfully been done elsewhere (18).

Conclusion
Children’s outcomes were not improved by doubling the dose
of cotrimoxazole to treat non-severe childhood pneumonia.
Because another study has identiﬁed similar failure rates with
a shorter course of a more expensive drug (3–5 days of amoxicillin) (17), we recommend testing the effectiveness of 3 days
of treatment with cotrimoxazole in children with non-severe
pneumonia. Periodic surveillance of the clinical effectiveness
of cotrimoxazole in both urban and rural areas is important in
guiding decisions on optimal ﬁrst-line therapy for non-severe
pneumonia. Further work is required to increase the speciﬁcity
of the deﬁnition of clinical failure. We recommend that further
research should be done using an observational study of children with non-severe pneumonia whose condition appears to
be the same at day 2 to determine whether they actually require
a change in therapy. Finally, close follow-up of all children is key
to decreasing morbidity and mortality from pneumonia. O
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Résumé
Essai contrôlé randomisé comparant l’efﬁcacité d’une dose standard et d’une double dose de
cotrimoxazole dans le traitement des pneumopathies infantiles au Pakistan
Objectif Les préoccupations grandissantes suscitées par la
résistance bactérienne au cotrimoxazole, recommandé comme
traitement de première intention par l’OMS pour faire face aux
pneumopathies sans signe de gravité, ont conduit à penser qu’il
ne s’agissait peut être pas du traitement optimal. Néanmoins, le
passage à d’autres agents antimicrobiens, tels que l’amoxicilline,
sera coûteux. Les auteurs ont comparé l’efﬁcacité clinique de
l’administration bijournalière d’une dose standard et d’une double
dose de cotrimoxazole dans le traitement des pneumopathies sans
signe de gravité chez l’enfant.
Méthodes On a mis en œuvre un essai multicentrique contrôlé
et randomisé dans sept consultations hospitalières externes et
dans deux programmes de santé communautaire. On a attribué
au hasard à 1143 enfants au total, âgés de 2 à 59 mois et atteints
de pneumopathie sans signe de gravité, un traitement comprenant
soit 4 mg de triméthoprime plus 20 mg de sulfaméthoxazole par
kilogramme de poids corporel, soit 8 mg de triméthoprime plus
40 mg de sulfaméthoxazole par kilogramme de poids corporel,
par voie orale, deux fois par jour, pendant 5 jours. Il y avait échec
thérapeutique lorsqu’un enfant nécessitait une modiﬁcation du
Bulletin of the World Health Organization | January 2005, 83 (1)

traitement, mourrait ou était perdu de vue. Une modiﬁcation
du traitement s’imposait chez les enfants dont l’état clinique
se détériorait (apparition d’un tirage sous-costal ou de signes
d’alerte) ou restait identique 48 h après le recrutement (c’est-à-dire
que la différence entre les rythmes respiratoires mesurés lors du
recrutement et 48 h après ne dépassait pas 5 respirations/minute).
Résultats On a analysé les résultats obtenus avec les 1134
enfants, dont 578 avaient reçu une dose standard de cotrimoxazole
et 556 une double dose. On a relevé un échec thérapeutique chez
112 enfants (19,4 %) du groupe soumis au traitement standard et
chez 118 enfants (21,2 %) du groupe recevant une double dose
(risque relatif 1,10, intervalle de conﬁance à 95 % : 0,87 - 1,37).
Une analyse multivariée a permis d’établir que le traitement avait
une plus forte probabilité d’échouer chez les enfants auxquels on
n’avait pas administré correctement le médicament (p = 0,001),
chez les enfants de moins de 12 mois (p = 0,004), chez ceux ayant
reçu auparavant des antibiotiques (p = 0,002), chez ceux dont le
rythme respiratoire était supérieur ou égal à 20 respirations/minute
et au point de coupure spéciﬁque à l’âge (p = 0,006) et chez ceux
provenant de zones urbaines (p = 0,042).
17
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Conclusion On a constaté une efficacité équivalente du
cotrimoxazole sous forme de dose standard et de double dose dans
le traitement des pneumopathies sans signe de gravité. Un suivi
étroit des patients est essentiel pour prévenir toute aggravation

Zeba A. Rasmussen et al.

de la maladie. L’échec clinique doit être déﬁni de manière plus
spéciﬁque. La surveillance tant dans les zones rurales qu’urbaines
est indispensable au développement de stratégies thérapeutiques
reposant sur les résultats cliniques.

Resumen
Ensayo controlado aleatorizado de comparación de la dosis estándar y la dosis doble de cotrimoxazol
contra la neumonía infantil en el Pakistán
Objetivo La creciente preocupación en torno a la resistencia
bacteriana al cotrimoxazol, producto recomendado por la OMS
como medicamento de primera línea para tratar la neumonía
no grave, ha llevado a pensar que ese tratamiento quizá no es
el más adecuado. Sin embargo, sustituirlo por otros agentes
antimicrobianos, como la amoxicilina, resulta costoso. Decidimos
comparar la eﬁcacia clínica de la dosis estándar y la dosis doble
de cotrimoxazol administrado dos veces al día como tratamiento
de la neumonía no grave en los niños.
Métodos Se llevó a cabo un ensayo multicéntrico controlado
aleatorizado en siete departamentos ambulatorios de hospital
y dos programas de salud comunitaria. Un total de 1143 niños
de 2 a 59 meses con neumonía no grave fueron asignados al
azar para recibir ya fuera 4 mg de trimetoprima más 20 mg de
sulfametoxazol/kg de peso corporal o bien 8 mg de trimetoprima
más 40 mg de sulfametoxazol/kg de peso corporal por vía oral
dos veces al día durante 5 días. Se consideraron casos de fracaso
terapéutico aquellos en los que el niño necesitaba un cambio de
tratamiento, fallecía o se perdía en el seguimiento. Se decidía
cambiar de tratamiento cuando la enfermedad se agravaba
(aparecían tiraje torácico o signos de peligro) o permanecía
estacionaria (se consideraba que así era cuando la frecuencia
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respiratoria no se desviaba más de 5 respiraciones/minuto de la
que tenía el niño al entrar a participar en el estudio).
Resultados Se analizaron los resultados conseguidos en 1134
niños: a 578 se les asignó la dosis ordinaria de cotrimoxazol, y a
556 la dosis doble. El tratamiento fracasó en 112 niños (19,4%)
en el grupo tratado de la forma habitual, y en 118 (21,2%) en el
grupo sometido a la dosis doble (riesgo relativo: 1,10; intervalo
de conﬁanza del 95% = 0,87–1,37). El análisis multifactorial
reveló que el tratamiento tenía más probabilidades de fracasar
entre los niños a los que no se les administraba correctamente el
medicamento (P = 0,001), los menores de 12 meses (P = 0,004),
los que habían usado antibióticos anteriormente (P = 0,002), los
que presentaban una frecuencia respiratoria  20 respiraciones/
minuto por encima del umbral especíﬁco para la edad (P = 0,006)
y los residentes en zonas urbanas (P = 0,042).
Conclusión El tratamiento estándar y la dosis doble de
cotrimoxazol fueron igual de eﬁcaces en los casos de neumonía no
grave. El seguimiento estrecho de los pacientes es esencial para
prevenir el empeoramiento de la enfermedad. Es preciso disponer de
unas deﬁniciones de fracaso clínico más especíﬁcas. La vigilancia,
tanto en las zonas rurales como en las urbanas, es esencial para poder
formular políticas de tratamiento basadas en los resultados clínicos.
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Table 2. Univariate analysis of relation between treatment failure and signiﬁcant variables at baseline among 1134 children
treated for non-severe pneumonia with either standard dose or double dose cotrimoxazole
Variable
Strength of cotrimoxazole
Double dose
Standard dose

Total no.
of children

Treatment
success (n = 904)

Treatment
failure (n = 230)

Relative riska

P-value

556
578

438
446

118
112

1.10 (0.87–1.37)

0.461

Median age in monthsb

1134

12 (6–22)

8 (4–18)

0.001

Mean age in monthsc

1134

15.7 (12.7)

13.7 (13.2)

0.032

577
557

437
467

140
90

1134

3 (2–5)

3 (2–5)

0.083

1134
456
678
879
1083
632
1002
300
201
45

3.6 (2.8)
379
525
687
867
499
797
243
157
33

4.2 (3.7)
77
153
192
216
133
205
57
44
12

0.022
1.33 (1.05–1.68)
1.47 (1.08–1.95)
0.73 (0.43–1.16)
1.09 (0.86–1.36)
1.09 (0.74–1.53)
0.92 (0.69–1.19)
1.10 (0.81–1.45)
1.33 (0.78–2.08)

0.020
0.017
0.211
0.504
0.731
0.558
0.562
0.262

731
16
282
48

584
9
226
28

147
7
56
20

0.98 (0.76–1.23)
2.19 (1.12–3.41)
0.98 (0.74–1.26)
2.16 (1.47–2.92)

0.877
0.028
0.865
0.001

293
117
175
1128

224
83
149
–0.90 (–1.67 to –0.05)

69
34
26
–0.80 ( –1.55 to 0.00)

1.23 (0.96–1.56)
1.51 (1.09 –2.00)
0.69 (0.47 –1.00)

0.110
0.015
0.052
0.301

316

237

79

1.35 (1.06–1.69)

0.017

64

42

22

1.77 (1.21–2.43)

0.006

Age categories
2–11 months
12–59 months
History at baseline
Median no. of days ill prior
to presentationb
Mean duration of illnessc
< 3 days
 3 days
Urban area
Cough
Difﬁculty breathing
Fever
Vomiting
Diarrhoea
Wheezing  3 times at any
time in the past
Currently being breastfed
Tight chest binding
Any treatment in past 7 daysd
Documented antibiotic use
in past 7 days
Examination at baseline
Wheezing
High respiratory ratee
Malnourishedf
Median weight-for-age scoreb
During the study
Wheezing at any time
after enrolment
Was not given medicine
correctly
a
b
c
d
e

f

1.50 (1.19 –1.86)

0.001

Values in parentheses are 95% conﬁdence intervals.
Values in parentheses are interquartile ranges.
Values in parentheses are standard deviations.
Deﬁned as treatment with antibiotics or other medicines.
A high respiratory rate was one in which the child had  20 breaths/minute above the age-adjusted WHO threshold for tachypnoea, that is  70 for children
aged 2–11 months and  60 for those aged 12–59 months.
Weight-for-age scores > 2 standard deviations below normal (15).
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Table 4. Characteristics of 1134 children treated for non-severe pneumonia, by study area
Study areaa

Variable

P-value

1.45 (1.06–1.99)

Urban (n = 879)

Rural (n = 255)

Treatment failure
Median age in monthsc
Male

192 (21.8)
10 (5–18)
551 (63.0)

38 (14.9)
17 (7–26)
148 (58.0)

1.16 (0.93–1.44)

0.017
<0.001
0.188

History at baseline
Median no. of days ill prior to presentationc
Fever
Cough
Difﬁculty breathing
Tight chest binding
Antibiotic use in past 7 days
Wheezing  3 times at any time in the past
Vomiting
Diarrhoea
Currently being breastfed
Any treatment in past 7 daysd

3 (2–5)
768 (87.4)
847 (96.4)
515 (58.6)
14 (1.6)
43 (4.9)
23 (2.6)
250 (28.4)
166 (18.9)
561 (63.8)
220 (25.0)

2 (1–3)
234 (91.8)
236 (92.5)
117 (45.9)
2 (0.8)
5 (2.0)
22 (8.6)
50 (19.6)
35 (13.7)
170 (66.7)
62 (24.3)

0.68 (0.45–1.02)
1.71 (1.18–2.48)
1.48 (1.20–1.84)
1.81 (0.49–6.65)
2.21 (0.96–5.10)
0.44 (0.32–0.60)
1.48 (1.12–1.95)
1.35 (0.98–1.87)
0.91 (0.72–1.14)
1.03 (0.80–1.33)

<0.001
0.059
0.015
<0.001
0.546
0.050
<0.001
0.005
0.062
0.415
0.869

Examination at baseline
High respiratory ratee
Wheezing
Malnutritionf

86 (9.8)
246 (28.0)
119 (13.6)

31 (12.2)
47 (18.4)
56 (22.0)

0.83 (0.60–1.15)
1.54 (1.16–2.06)
0.65 (0.51–0.84)

0.293
0.002
0.002

During the study
Wheezing at any time during the study
Was not given medicine correctly

263 (29.9)
43 (4.9)

53 (20.8)
21 (8.2)

1.47 (1.12–1.94)
0.67 (0.46–0.96)

0.004
0.046

a
b
c
d
e

f

B

Relative riskb

Values are numbers (percentages) unless otherwise indicated.
Values in parentheses in this column are 95% conﬁdence intervals.
Values in parentheses are interquartile ranges.
Deﬁned as treatment with antibiotics or other medicines.
A high respiratory rate was one in which the child had  20 breaths/minute above the age-adjusted WHO threshold for tachypnoea, that is  70 for children
aged 2–11 months and  60 for those aged 12–59 months.
Weight-for-age scores > 2 standard deviations below normal (15).
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